enGene Holdings Inc. (ENGN)

15,50 +0,78 (+5,30%) Börsenschluss: 04:00PM EDT

enGene Holdings Inc.

7171 Rue Frederick Banting
Saint-Laurent, QC H4S 1Z9
Canada
514 332 4888
https://www.engene.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 31

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jason D. Hanson Esq., J.D.	CEO & Director	656,58k	N/A	1969
Dr. Alex Nichols Ph.D.	President & COO	504,44k	N/A	1986
Dr. James C. Sullivan M.Sc., Ph.D.	Chief Scientific Officer	524,29k	N/A	1979
Dr. Anthony T. Cheung Ph.D.	Co-Founder & CTO	341,75k	N/A	1972
Mr. John C. Brown D.Sc., FRSC, Ph.D.	Co-Founder and Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. David Ryan Daws	CFO & Head of Business Development	N/A	N/A	1974
Mr. Lee G. Giguere	Chief Legal Officer & Corporate Secretary	N/A	N/A	1981
Ms. Sharon Tan	VP of Project Management & Head of Program Management	N/A	N/A	N/A
Dr. Richard P. Bryce MBChB, MFPM, MRCGP	Chief Medical Officer	N/A	N/A	1957
Dr. Raj Pruthi M.D.	Senior VP of Urologic Oncology & Clinical Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Corporate Governance

enGene Holdings Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.